Anti-Human CD71 (Clone T56/14) – Purified in vivo GOLD™ Functional Grade

The T56/14 clone is a monoclonal antibody that reacts with human CD71 (also known as transferrin receptor or TfR1) and is specifically designed for in vivo research applications in mouse studies.

Primary Applications in Mouse Studies

The T56/14 antibody is commonly used in xenograft tumor models where human cancer cells are implanted into immunocompromised mice. Since this antibody specifically targets human CD71, it allows researchers to study human tumor cells within a mouse host without cross-reacting with mouse tissues.

Mechanism and Target

CD71 is a type II homodimeric transmembrane glycoprotein expressed on proliferating cells, reticulocytes, and erythroid precursors. It plays a crucial role in cellular proliferation and iron import from transferrin into cells. The protein is particularly relevant for cancer research because it's expressed at high levels on malignant cells, and its expression correlates with cancer progression.

Antibody Characteristics for In Vivo Use

The T56/14 antibody has several important characteristics that make it suitable for in vivo mouse studies:

• It's a non-neutralizing antibody that doesn't inhibit transferrin binding, making it useful for tracking and studying CD71 without interfering with its normal function
• The antibody has low endotoxin levels (<2EU/mg), which is essential for in vivo applications to avoid inflammatory responses
• It's formulated in PBS without stabilizers or preservatives, making it compatible with in vivo administration

Research Applications

Beyond basic xenograft studies, the T56/14 clone is used in various in vivo research contexts including flow cytometry and immunoprecipitation studies of tumor samples extracted from treated mice. This allows researchers to analyze CD71 expression levels and distribution in tumor tissues after various experimental treatments.

The antibody is particularly valuable for studying cancer progression, cellular proliferation mechanisms, and iron metabolism in human tumor models established in mice, providing insights into how these processes might be targeted therapeutically.

The T56/14 antibody is most commonly used to detect human CD71 (transferrin receptor, also known as TFRC) in various immunological assays such as flow cytometry, immunoprecipitation, and western blotting. In the scientific literature, researchers frequently use T56/14 in combination with several other antibodies or markers, depending on the experimental goal:

• Leukocyte subset markers: Common combinations involve antibodies against surface markers for different immune cell subsets (e.g., CD3 for T cells, CD19 for B cells, CD45 for leukocytes), allowing characterization of CD71 expression on specific cell types.
• Proliferation and activation markers: CD71 is often paired with proliferation markers like Ki-67 or activation markers like CD25 and HLA-DR to study cell growth or activation states.
• CD34: Frequently used in hematopoietic or stem cell research along with CD71 to identify erythroid precursors or progenitor populations.

These combinations are guided by the biology of CD71, which is highly expressed on proliferating and activated cells, as well as on erythroid precursors.

Other proteins or antibodies that are less directly related but sometimes assessed in tandem with CD71 (T56/14) in broader panels include:

• CD235a (Glycophorin A) and CD36, when dissecting erythroid differentiation.
• CD27, a marker frequently analyzed in immunophenotyping panels, although T14 (mentioned in your results) is not directly related to CD71 but rather to the CD27 molecule.

Summary of common combinations with T56/14:

• Antibodies to lineage or differentiation markers: CD3, CD19, CD34, CD45
• Proliferation/activation markers: Ki-67, CD25, HLA-DR
• Erythroid markers (in erythropoiesis): CD235a, CD36

The exact combination depends on the experimental design, focus, and cell types under investigation. Specific literature examples will list unique panels, but these markers are consistent with the biology of CD71 and its applications.

There are no directly relevant or widely cited key findings in scientific literature specifically associated with "clone T56/14." None of the major search results indicate recognition or discussion of a "clone T56/14" antibody, cell line, or genetic construct in well-known journals or databases. The search results reference the following, which do not relate directly to "clone T56/14":

• Isolation of human hematopoietic progenitors and associated methodologies, which mention various clones but do not specifically identify T56/14.
• Studies of the TRIM56 protein (not a clone), detailing its function in antiviral immunity and structural requirements, but this is unrelated to a "clone T56/14".
• Engineering tests on T56 turbine blades for aircraft, which are mechanical engineering reports with no biological or molecular clone involved.

If your query refers to an antibody (often called "clone X"), a transgenic line, or a plasmid referenced as T56/14, there is no evidence from authoritative literature that it is widely cited or recognized in the current scientific record. Alternative explanations for your query could include a typographical error in the clone name, or a reference to a reagent of very limited or niche use.

If clarification or a corrected clone reference can be provided, a more targeted literature search can be performed.

Dosing regimens for clone T56/14 are not explicitly detailed in the available search results, and there is no direct reference to this clone in the context of mouse models or antibody dosing guidelines provided. As such, I cannot provide authoritative dosing schedules or variations specific to clone T56/14 across differing mouse models based solely on the retrieved documents.

If clone T56/14 refers to an antibody (common with the T numbering), standard practice for monoclonal antibodies in vivo involves the following considerations (based on general antibody dosing guides for mice):

• Dose amounts: Most antibodies are administered at doses ranging from 100–500??g per mouse, typically via intraperitoneal injection.
• Frequency: Common schedules are every 3–4 days, with application frequency sometimes adjusted depending on the antibody's pharmacokinetics and the experimental goal.
• Model variation: Dosing can vary between models (such as C57BL/6 versus BALB/c, or transgenic vs immunodeficient mice), with adjustment based on factors like disease severity, challenge dose, and desired immunomodulation.

Without more direct data on clone T56/14:

• If it is used for T cell depletion or immune modulation, doses and schedules would likely be analogous to other depleting antibodies (e.g., anti-CD4, anti-CD8), usually 200–250??g per mouse, 2–3 times per week.
• If clone T56/14 is related to a specific disease or antigen, protocols may differ substantially depending on target antigen abundance, disease model, and pharmacodynamic endpoints — but no specific protocol for T56/14 is documented in the supplied results.

Key Limitations:

• None of the search results provide dosing regimens specifically for clone T56/14.
• Any further details would require either direct literature reference or experimental protocols from primary sources, which are not present here.

If you have more information on what clone T56/14 targets or its application area, I can offer more tailored protocol guidance using general principles from antibody dosing in mouse models. For now, dosing strategies would follow standard monoclonal antibody protocols as outlined above.